We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
EPCORITAMAB WITH RITUXIMAB + LENALIDOMIDE (R2) PROVIDES DURABLE RESPONSES IN HIGH‐RISK FOLLICULAR LYMPHOMA, REGARDLESS OF POD24 STATUS.
- Authors
Belada, D.; Falchi, L.; Leppä, S.; Vermaat, J. S.; Holte, H.; Hutchings, M.; Lugtenburg, P.; de Vos, S.; Abrisqueta, P.; Nijland, M.; Merryman, R. W.; Christensen, J. H.; Wahlin, B. E.; Linton, K. M.; Wang, L.; Abbas, A.; Rana, A.; Quadri, S.; Sureda, A.
- Abstract
Epcoritamab was dosed QW in cycles 1-3, Q2W in cycles 4-9, and Q4W in cycles >=10 (2a) or QW in cycles 1-2 and Q4W in cycles >=3 (2b) for <=2 y. B Results: b As of 31 October 2022, 109 I R i / I R i FL patients had received epcoritamab 48 mg + I R i SP 2 sp in 2a and 2b. Notably, patients achieved higher ORR/CMR rates with epcoritamab + I R i SP 2 sp versus their immediate prior treatment line (ORR, 97% vs. 85%; CMR, 86% vs. 60%). There is no standard treatment approach for patients with high-risk, relapsed or refractory ( I R i / I R i ) FL (high-risk subgroups in B Table b ).
- Subjects
FOLLICULAR lymphoma; RITUXIMAB; LENALIDOMIDE; BISPECIFIC antibodies; ALKYLATING agents
- Publication
Hematological Oncology, 2023, Vol 41, p125
- ISSN
0278-0232
- Publication type
Article
- DOI
10.1002/hon.3163_84